medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2015; 14 (3)


Mycophenolic acid induces apoptosis of hepatic stellate cells in an in vitro model of HCV

Best J, Zahn A, Beilfuß A, Sydor S, Fingas C, Jan-Peter Sowa, Anastasiou O, Cicinnati V, Gerken G, Canbay A, Bechmann LP

Idioma: Ingles.
Referencias bibliográficas: 20
Paginas: 396-403
Archivo PDF: 177.87 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Asselah T, Bieche I, Sabbagh A, Bedossa P, Moreau R, Valla D, Vidaud M, et al. Gene expression and hepatitis C virus infection. Gut 2009:58:846-58. doi: gut.2008.166348 [pii] 10.1136/gut.2008.166348.

  2. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013; 33(Suppl. 1): 56-62. doi: 10.1111/liv.12062.

  3. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206. doi: 10.1016/j.bpg.2011.02.005.

  4. Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol 2013; 3: 1473-92. doi: 10.1002/cphy.c120035.

  5. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, Gores GJ. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38: 1188-98. doi: 10.1053/ jhep.2003.50472 S0270913903008760 [pii].

  6. Xu L, Hui AY, Albanis E, Arthur MJ, O’Byrne SM, Blaner WS, Mukherjee P, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005; 54: 142-51. doi: 10.1136/gut.2004.042127.

  7. Gieseler RK, Marquitan G, Schlattjan M, Sowa JP, Bechmann LP, Timm J, Roggendorf M, et al. Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C. J Viral Hepat 2011; 18: 760-7. doi: JVH1362 [pii] 10.1111/j.1365-2893.2010.01362.x. 403 Mycophenolic acid induces apoptosis of hepatic stellate cells in an in vitro model of HCV. , 2015; 14 (3): 396-403

  8. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL receptor-2/ death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003; 37: 87-95. doi: 10.1053/ jhep.2003.50002.

  9. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2008; 27(Suppl. 1): S71-83. doi: 10.1038/ onc.2009.45.

  10. Greupink R, Bakker HI, Reker-Smit C, van Loenen- Weemaes AM, Kok RJ, Meijer DK, Beljaars L, et al. Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. J Hepatol 2005; 43: 884-92. doi: 10.1016/j.jhep.2005.04.014.

  11. Andriulli A, Di Marco V, Margaglione M, Ippolito AM, Fattovich G, Smedile A, Valvano MR, et al. Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. J Hepatol 2014; 60: 16-21. doi: S0168-8278(13)00594- 1 [pii] 10.1016/j.jhep.2013.07.040.

  12. Wells MM, Roth LS, Marotta P, Levstik M, Mason AL, Bain VG, Chandok N, et al. Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review. Saudi J Gastroenterol 2013; 19: 223-9. doi: SaudiJGastroenterol_ 2013_19_5_223_118133 [pii] 10.4103/1319-3767.118133.

  13. Coilly A, Roche B, Duclos-Vallee JC, Samuel D. Management of HCV transplant patients with triple therapy. Liver Int 2014; 34(Suppl. 1): 46-52. doi: 10.1111/liv.12406.

  14. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60: 530-7. doi: 10.1016/j.jhep.2013.11.009.

  15. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-23. doi: 10.1016/S0140-6736(13)62121-2.

  16. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-5. doi: 10.1111/ajt.12209.

  17. Kornberg A, Kupper B, Wilberg J, Tannapfel A, Thrum K, Barthel E, Hommann M, et al. Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients. Transpl Infect Dis 2007; 9: 295-301. doi: TID228 [pii] 10.1111/j.1399-3062.2007.00228.x.

  18. Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, Hartmann DJ, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 51-61. doi: kid140 [pii] 10.1046/j.1523-1755.2000.00140.x.

  19. Bridle KR, Popa C, Morgan ML, Sobbe AL, Clouston AD, Fletcher LM, Crawford DH. Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl 2009; 15: 1315-24. doi: 10.1002/ lt.21804.

  20. Firpi RJ, Soldevila-Pico C, Morelli GG, Cabrera R, Levy C, Clark VC, Suman A, et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci 2010; 55: 196-203. doi: 10.1007/ s10620-009-0981-3.




2020     |     www.medigraphic.com